BEAM

Beam Therapeutics Inc.

There isn't enough reported data to score BEAM yet.

OSCR

Oscar Health, Inc.

69
Fundamentals85/ 100
Valuation50/ 100
Upside potential61/ 100
Risk potential35/ 100

OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.

BEAM Fundamentals

MetricStatus
Healthy
Under pressure
Weak
Unavailable

BEAM's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.

OSCR Fundamentals

MetricStatus
Strong
Healthy
Strong
Strong

OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.

BEAM PE Valuation

BEAM has no meaningful PE right now: it lost money over the past year.

OSCR PE Valuation

CHEAPFAIREXPENSIVE41x83x124x166x
CHEAPFAIREXPENSIVE41x83x124x166x
LevelPEPriceVs current
Forward12x$31.94—
Current13x$31.94—
Cheap21x$52.73+65%
Fair35x$87.23+173%
Expensive130x$322+907%

Historical ranges are pointers, not guarantees.

OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.

BEAM Forward outlook

MetricOutlook
--
Losses growing
Strong decline
--
Limited
Low

Analysts expect BEAM's losses to grow, with revenue declining. However, they disagree widely on these estimates.

OSCR Forward outlook

MetricOutlook
Improving
Strong growth
Strong growth
Strongly improving
Limited
Moderate

Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.

BEAM Risk to reward

ScenarioChangePrice
UpsideUnknown—
DownsideUnknown—

Calculated from the latest close: $24.03 on Nov 12.

There is not enough scenario data to compare BEAM and OSCR's risk to reward.

OSCR Risk to reward

ScenarioChangePrice
Upside+55%$49.45
Downside-35%$20.78

Calculated from the latest close: $31.94 on Nov 12.

There is not enough scenario data to compare BEAM and OSCR's risk to reward.

BEAM Earnings Per Share

Q4 2023: $-1.72Q1 2024: $-1.60Q2 2024: $-1.63Q3 2024: $-1.58Q4 2024: $-4.58Q1 2025: $-4.61Q2 2025: $-4.50Q3 2025: $-4.43Q4 2025: $-0.81Q1 2026: $-0.48Q2 2026: $-0.66Q3 2026: $-0.84
Q4 2023: $-1.72Q1 2024: $-1.60Q2 2024: $-1.63Q3 2024: $-1.58Q4 2024: $-4.58Q1 2025: $-4.61Q2 2025: $-4.50Q3 2025: $-4.43Q4 2025: $-0.81Q1 2026: $-0.48Q2 2026: $-0.66Q3 2026: $-0.84
QuarterTTM EPSYoY
Q3 2026-$0.84+$3.59
Q2 2026-$0.66+$3.84
Q1 2026-$0.48+$4.13
Q4 2025-$0.81+$3.77
Q3 2025-$4.43-$2.85
Q2 2025-$4.50-$2.87
Q1 2025-$4.61-$3.01
Q4 2024-$4.58-$2.86

BEAM is still losing money, but far less than before: $0.84 per share over the past year, against $7.05 at its worst in mid-2021.

OSCR Earnings Per Share

Q4 2023: $-1.22Q1 2024: $-0.42Q2 2024: $-0.15Q3 2024: $-0.08Q4 2024: $0.10Q1 2025: $0.40Q2 2025: $-0.69Q3 2025: $-1.00Q4 2025: $-1.69Q1 2026: $-0.54Q2 2026: $1.45Q3 2026: $2.47Forward: $2.61
Q4 2023: $-1.22Q1 2024: $-0.42Q2 2024: $-0.15Q3 2024: $-0.08Q4 2024: $0.10Q1 2025: $0.40Q2 2025: $-0.69Q3 2025: $-1.00Q4 2025: $-1.69Q1 2026: $-0.54Q2 2026: $1.45Q3 2026: $2.47Forward: $2.61
QuarterTTM EPSYoY
Forward$2.61+5.6%
Q3 2026$2.47+$3.47
Q2 2026$1.45+$2.14
Q1 2026-$0.54-235%
Q4 2025-$1.69-1790%
Q3 2025-$1.00-$0.92
Q2 2025-$0.69-$0.54
Q1 2025$0.40+$0.82
Q4 2024$0.10+$1.32

OSCR has the edge over BEAM on earnings quality, reporting a profit while its opponent remains loss making.

BEAM Quarterly Revenue

Q4 2023: $316MQ1 2024: $7MQ2 2024: $12MQ3 2024: $14MQ4 2024: $30MQ1 2025: $7MQ2 2025: $8MQ3 2025: $10MQ4 2025: $114MQ1 2026: $32MQ2 2026: $490,000Q3 2026: $307,000
Q4 2023: $316MQ1 2024: $7MQ2 2024: $12MQ3 2024: $14MQ4 2024: $30MQ1 2025: $7MQ2 2025: $8MQ3 2025: $10MQ4 2025: $114MQ1 2026: $32MQ2 2026: $490,000Q3 2026: $307,000
QuarterRevenueYoY
Q3 2026$307K-97%
Q2 2026$490K-94%
Q1 2026$31.7M+325%
Q4 2025$114.1M+280%
Q3 2025$9.7M-32%
Q2 2025$8.5M-28%
Q1 2025$7.5M+0.8%
Q4 2024$30.1M-90%

BEAM's revenue is growing: $307,000 last quarter, down 97% from the same quarter a year ago.

OSCR Quarterly Revenue

Q4 2023: $1.4BQ1 2024: $2.1BQ2 2024: $2.2BQ3 2024: $2.4BQ4 2024: $2.4BQ1 2025: $3BQ2 2025: $2.9BQ3 2025: $3BQ4 2025: $2.8BQ1 2026: $4.6BQ2 2026: $4.9BQ3 2026: $5.1B
Q4 2023: $1.4BQ1 2024: $2.1BQ2 2024: $2.2BQ3 2024: $2.4BQ4 2024: $2.4BQ1 2025: $3BQ2 2025: $2.9BQ3 2025: $3BQ4 2025: $2.8BQ1 2026: $4.6BQ2 2026: $4.9BQ3 2026: $5.1B
QuarterRevenueYoY
Q3 2026$5.1B+72%
Q2 2026$4.9B+70%
Q1 2026$4.6B+53%
Q4 2025$2.8B+17%
Q3 2025$3B+23%
Q2 2025$2.9B+29%
Q1 2025$3B+42%
Q4 2024$2.4B+67%

OSCR has the edge over BEAM on sales, with more consistent year-over-year improvement.

BEAM Free Cash Flow

Q4 2023: $131MQ1 2024: −$102MQ2 2024: −$85MQ3 2024: −$90MQ4 2024: −$79MQ1 2025: −$107MQ2 2025: −$80MQ3 2025: −$86MQ4 2025: −$87MQ1 2026: −$131MQ2 2026: −$69MQ3 2026: −$112M
Q4 2023: $131MQ1 2024: −$102MQ2 2024: −$85MQ3 2024: −$90MQ4 2024: −$79MQ1 2025: −$107MQ2 2025: −$80MQ3 2025: −$86MQ4 2025: −$87MQ1 2026: −$131MQ2 2026: −$69MQ3 2026: −$112M
QuarterFree cash flowYoY
Q3 2026-$112M-$25.5M
Q2 2026-$68.5M+$11.1M
Q1 2026-$130.7M-$23.8M
Q4 2025-$87M-$7.7M
Q3 2025-$86.5M+$3.2M
Q2 2025-$79.6M+$5.4M
Q1 2025-$106.9M-$4.8M
Q4 2024-$79.3M-160%

BEAM has burned cash in almost every quarter: −$398M over the past year, against −$352M the year before.

OSCR Free Cash Flow

Q4 2023: $291MQ1 2024: $628MQ2 2024: $490MQ3 2024: −$508MQ4 2024: $340MQ1 2025: $870MQ2 2025: $500MQ3 2025: −$974MQ4 2025: $663MQ1 2026: $2.6BQ2 2026: $2.1BQ3 2026: −$1.2B
Q4 2023: $291MQ1 2024: $628MQ2 2024: $490MQ3 2024: −$508MQ4 2024: $340MQ1 2025: $870MQ2 2025: $500MQ3 2025: −$974MQ4 2025: $663MQ1 2026: $2.6BQ2 2026: $2.1BQ3 2026: −$1.2B
QuarterFree cash flowYoY
Q3 2026-$1.2B-$238.2M
Q2 2026$2.1B+316%
Q1 2026$2.6B+200%
Q4 2025$662.8M+95%
Q3 2025-$973.7M-$466M
Q2 2025$499.8M+2.1%
Q1 2025$869.5M+38%
Q4 2024$340M+17%

OSCR has the edge over BEAM on cash generation, producing positive trailing cash flow while its opponent burns cash.

BEAM Total Shares

Q4 2023: 77MQ1 2024: 82MQ2 2024: 82MQ3 2024: 82MQ4 2024: 82MQ1 2025: 88MQ2 2025: 102MQ3 2025: 103MQ4 2025: 99MQ1 2026: 103MQ2 2026: 104MQ3 2026: 105M
Q4 2023: 77MQ1 2024: 82MQ2 2024: 82MQ3 2024: 82MQ4 2024: 82MQ1 2025: 88MQ2 2025: 102MQ3 2025: 103MQ4 2025: 99MQ1 2026: 103MQ2 2026: 104MQ3 2026: 105M
PeriodChange %Net change
Quarterly+0.4%+372K shares
1 year+2.1%+2.1M shares
3 years+32%+25.7M shares
5 years+58%+38.3M shares
Available history+241%+74M shares

BEAM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.

OSCR Total Shares

Q4 2023: 222MQ1 2024: 294MQ2 2024: 304MQ3 2024: 243MQ4 2024: 266MQ1 2025: 306MQ2 2025: 256MQ3 2025: 259MQ4 2025: 262MQ1 2026: 330MQ2 2026: 333MQ3 2026: 346M
Q4 2023: 222MQ1 2024: 294MQ2 2024: 304MQ3 2024: 243MQ4 2024: 266MQ1 2025: 306MQ2 2025: 256MQ3 2025: 259MQ4 2025: 262MQ1 2026: 330MQ2 2026: 333MQ3 2026: 346M
PeriodChange %Net change
Quarterly+3.9%+13M shares
1 year+34%+87.2M shares
3 years+55%+123M shares
5 years+66%+138M shares
Available history+71%+143M shares

OSCR has 346M diluted shares, up 34% from a year ago.

BEAM Net Leverage

BEAM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

OSCR Net Leverage

Q1 2024: -217.7xQ2 2024: -24.0xQ3 2024: -10.1xQ4 2024: -13.7xQ1 2025: -9.7xQ1 2026: -110.0xQ2 2026: -5.5xQ3 2026: -4.2x
Q1 2024: -217.7xQ2 2024: -24.0xQ3 2024: -10.1xQ4 2024: -13.7xQ1 2025: -9.7xQ1 2026: -110.0xQ2 2026: -5.5xQ3 2026: -4.2x
QuarterNet LeverageStatus
Q3 2026-4.2xNet Cash
Q2 2026-5.5xNet Cash
Q1 2026-110.0xNet Cash
Q1 2025-9.7xNet Cash
Q4 2024-13.7xNet Cash
Q3 2024-10.1xNet Cash
Q2 2024-24.0xNet Cash
Q1 2024-217.7xNet Cash

OSCR has more cash than debt.

BEAM Weekly Momentum

MetricValueStatus
RSI44.3Neutral
Stochastic36.5Neutral

BEAM's weekly RSI is 44 (neutral) and its Stochastic is 37 (neutral).

OSCR Weekly Momentum

MetricValueStatus
RSI58.7Neutral
Stochastic44.9Neutral

OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).

BEAM PE vs Healthcare Sector

BEAM has no meaningful PE right now: it lost money over the past year.

OSCR PE vs Healthcare Sector

MetricOSCRSector medianRelative
PE13x26x50% below
PE %33532 pts below

OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.

BEAM Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$25.03.7% below
20 week MA$26.911% below
50 week MA$27.814% below
100 week MA$25.03.7% below
200 week MA$26.710% below

BEAM is in a downtrend: it's below all five of its weekly moving averages, and 10% below its 200-week average.

OSCR Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$31.22.3% above
20 week MA$31.12.8% above
50 week MA$22.939% above
100 week MA$19.365% above
200 week MA$15.5106% above

OSCR has the edge over BEAM on trend strength, trading above more of its moving averages.

BEAM Yearly ROI

YearStart priceEnd priceROI
2020$20.6$87.8+326%
2021$87.8$86.5-1.5%
2022$86.5$40.4-53%
2023$40.4$27.2-33%
2024$27.2$26.6-2.3%
2025$26.6$28.0+5.2%
2026 YTD$28.0$24.0-14%

BEAM's yearly returns have swung widely, from +326% in 2020 to −53% in 2022. It's down 14% so far in 2026.

OSCR Yearly ROI

YearStart priceEnd priceROI
2021$31.0$8.02-74%
2022$8.02$2.21-72%
2023$2.21$9.15+314%
2024$9.15$13.8+51%
2025$13.8$14.9+8%
2026 YTD$14.9$31.9+114%

OSCR has the edge over BEAM on returns for 2026, with the stronger performance.

Give your agent the market.

Get API key